Two ongoing phase III studies evaluate NIRA + AAP versus placebo + AAP in patients with mCRPC2 and metastatic castration-sensitive prostate cancer.10 For MAGNITUDE,2 the primary analysis showed a statistically significant and clinically meaningful improvement for rPFS with NIRA + AAP for patients with BRCA1/2 alterations (HR = 0.533 [95% CI, 0.361-0.789; 2-sided P = .0014]) as well as the combined HRR gene altered population (HR = 0.729 [95% CI, 0.556-0.956; P = .0217]). Here, BRCA1 is linked to prostate cancer.